Financial reports
10-K
2023 FY
Annual report
7 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
17 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K
2022 FY
Annual report
2 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K/A
2021 FY
Annual report (amended)
28 Apr 22
Current reports
8-K
Termination of a Material Definitive Agreement
14 Mar 24
8-K
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
8-K
Entry into a Material Definitive Agreement
5 Mar 24
8-K/A
Independent Auditor’s Report
23 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Departure of Directors or Certain Officers
27 Nov 23
8-K
Entry into a Material Definitive Agreement
13 Nov 23
8-K
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
31 Oct 23
8-K
Departure of Directors or Certain Officers
25 Sep 23
Registration and prospectus
S-8
Registration of securities for employees
12 Jan 24
8-A12G
Registration of securities
8 Dec 23
D/A
$60.25 mm in other securities, sold $60.25 mm, 2 investors
4 Dec 23
D
$60.25 mm in other securities, sold $60.25 mm, 2 investors
1 Dec 23
S-3/A
Shelf registration (amended)
1 Dec 23
S-3
Shelf registration
25 Oct 23
S-8
Registration of securities for employees
17 Aug 23
S-8
Registration of securities for employees
5 May 22
424B5
Prospectus supplement for primary offering
6 Apr 22
424B5
Prospectus supplement for primary offering
25 Oct 21
Proxies
DEFA14A
Additional proxy soliciting materials
14 Feb 24
DEF 14A
Definitive proxy
14 Feb 24
PRE 14A
Preliminary proxy
31 Jan 24
DEFA14A
Additional proxy soliciting materials
13 Nov 23
DEFA14A
Additional proxy soliciting materials
13 Jun 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
18 Apr 23
DEFR14A
Revised proxy
3 May 22
DEF 14A
Definitive proxy
3 May 22
Other
EFFECT
Notice of effectiveness
4 Dec 23
CORRESP
Correspondence with SEC
1 Dec 23
UPLOAD
Letter from SEC
30 Oct 23
CORRESP
Correspondence with SEC
30 Oct 23
EFFECT
Notice of effectiveness
17 Aug 20
CORRESP
Correspondence with SEC
12 Aug 20
UPLOAD
Letter from SEC
11 Aug 20
CT ORDER
Confidential treatment order
12 May 20
EFFECT
Notice of effectiveness
7 Feb 20
CORRESP
Correspondence with SEC
4 Feb 20
Ownership
4
TIMOTHY A SPRINGER
26 Mar 24
4
TIMOTHY A SPRINGER
20 Mar 24
4
TIMOTHY A SPRINGER
18 Mar 24
SC 13G/A
FMR LLC
11 Mar 24
SC 13G/A
MANGROVE PARTNERS IM, LLC
14 Feb 24
SC 13G/A
Artal International S.C.A.
9 Feb 24
SC 13G
FMR LLC
9 Feb 24
4
Michael Singer
4 Jan 24
4
Blaine Davis
4 Jan 24
4
Christopher M Jewell
4 Jan 24